Healthcare provider profile · identity verified

Ryan Paul Floyd, M.D.

Family Practice · LATROBE, PA · NPI 1699112797

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	325	91
Lisinopril	Lisinopril	254	74
Amlodipine Besylate	Amlodipine Besylate	192	53
Rosuvastatin Calcium	Rosuvastatin Calcium	178	50
Levothyroxine Sodium	Levothyroxine Sodium	161	42
Pantoprazole Sodium	Pantoprazole Sodium	142	37
Metformin Hcl	Metformin Hcl	127	33
Sertraline Hcl	Sertraline Hcl	124	22
Omeprazole	Omeprazole	123	29
Tamsulosin Hcl	Tamsulosin Hcl	120	26
Gabapentin	Gabapentin	108	24
Escitalopram Oxalate	Escitalopram Oxalate	102	20
Albuterol Sulfate Hfa	Albuterol Sulfate	101	26
Mounjaro	Tirzepatide	95	17
Simvastatin	Simvastatin	86	19
Metoprolol Tartrate	Metoprolol Tartrate	85	23
Allopurinol	Allopurinol	68	18
Losartan Potassium	Losartan Potassium	68	20
Synjardy Xr	Empagliflozin/Metformin Hcl	59	13
Zolpidem Tartrate	Zolpidem Tartrate	59	suppressed
Metoprolol Succinate	Metoprolol Succinate	58	15
Jardiance	Empagliflozin	57	13
Clopidogrel	Clopidogrel Bisulfate	52	11
Alprazolam	Alprazolam	51	suppressed
Xarelto	Rivaroxaban	50	13
Finasteride	Finasteride	49	15
Ozempic	Semaglutide	49	suppressed
Citalopram Hbr	Citalopram Hydrobromide	47	suppressed
Tramadol Hcl	Tramadol Hcl	47	11
Furosemide	Furosemide	45	14
Eliquis	Apixaban	44	suppressed
Valsartan	Valsartan	44	14
Potassium Chloride	Potassium Chloride	41	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	suppressed
Montelukast Sodium	Montelukast Sodium	39	suppressed
Spironolactone	Spironolactone	39	suppressed
Trulicity	Dulaglutide	39	suppressed
Aripiprazole	Aripiprazole	37	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	36	11
Hydrochlorothiazide	Hydrochlorothiazide	34	12
Fluconazole	Fluconazole	33	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	suppressed
Celecoxib	Celecoxib	32	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	31	21
Duloxetine Hcl	Duloxetine Hcl	31	suppressed
Metformin Hcl Er	Metformin Hcl	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Trazodone Hcl	Trazodone Hcl	31	suppressed
Meloxicam	Meloxicam	30	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	12
Irbesartan	Irbesartan	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	11
Synthroid	Levothyroxine Sodium	25	suppressed
Famotidine	Famotidine	24	11
Bumetanide	Bumetanide	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Hydrocortisone	Hydrocortisone	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	suppressed
Symproic	Naldemedine Tosylate	20	suppressed
Azithromycin	Azithromycin	19	suppressed
Chlorzoxazone	Chlorzoxazone	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	11
Propranolol Hcl	Propranolol Hcl	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Atenolol	Atenolol	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Lovastatin	Lovastatin	17	suppressed
Motegrity	Prucalopride Succinate	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Cephalexin	Cephalexin	16	14
Chlorthalidone	Chlorthalidone	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Methylprednisolone	Methylprednisolone	15	suppressed
Pravastatin Sodium	Pravastatin Sodium	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Kerendia	Finerenone	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Constulose	Lactulose	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Minocycline Hcl	Minocycline Hcl	13	suppressed
Prednisone	Prednisone	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Dexamethasone	Dexamethasone	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Topiramate	Topiramate	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error